Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)

 TAIPEI, July 28, 2026 /PRNewswire/ -- Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial evaluating YA-101, its flagship candidate for the treatment of Multiple System Atrophy (MSA). 

Dasher Neuroscience Holdings Inc. Top-line clinical data from the trial are expected in the first quarter of 2027. In parallel, Dasher Neuroscience is active…READ FULL ARTICLE